Our lead program, NDV-01 for non-muscle invasive bladder cancer (NMIBC), is advancing into the Phase 3 RESCUE registrational program. Sepranolone, our second program, targets compulsive behaviors through modulation of GABAA receptor activity and is advancing toward a Phase 2 trial in Prader-Willi syndrome.
NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) designed to enable prolonged bladder exposure and controlled local drug release. It arrives ready to use and is instilled in under five minutes, in the urologist's office.
Learn More About NDV-01
Sepranolone is a novel clinical candidate targeting compulsive behaviors through modulation of GABAA receptor activity. Prior clinical and preclinical data support the potential for Sepranolone to have a beneficial effect on food craving, appetite and compulsive behaviors.
Learn More About Sepranolone
